Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.46 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.43 |
| ▸ | DNASE1 | P24855 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336977 | 0.81 | POLB (0.60) | POLBHPGDMAPK1MEN1KMT2A | |
| SCHEMBL23997184 | 0.81 | POLB (0.60) | POLBHPGDMAPK1MEN1KMT2A | |
| SCHEMBL5242312 | 0.80 | POLB (0.52) | POLBMDM2ERCC1DNASE1FEN1 | |
| SCHEMBL5243128 | 0.79 | POLB (0.51) | POLBMDM2ERCC1DNASE1FEN1 | |
| SCHEMBL5240527 | 0.76 | SIRT2 (0.54) | POLBERCC1DNASE1FEN1ERCC4 | |
| SCHEMBL5241130 | 0.75 | MAPK9 (0.67) | MDM2ERCC1DNASE1FEN1ERCC4 | |
| SCHEMBL5243743 | 0.75 | POLB (0.53) | POLBMDM2ERCC1DNASE1FEN1 | |
| SCHEMBL14339623 | 0.73 | LMNA (0.55) | POLBERCC1DNASE1FEN1ERCC4 | |
| SCHEMBL5245528 | 0.72 | ERCC1 (0.51) | POLBMDM2ERCC1DNASE1FEN1 | |
| SCHEMBL5857428 | 0.71 | TNKS (0.46) | ERCC1DNASE1FEN1ERCC4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115644-B2 | Heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-10-03 | — | — | US | claimed |
| EP-1539708-B1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1539708-B1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7115644-B2 | Heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1539708-A1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040192748-A1 | Heterocyclic compounds | BOEHRINGER INGELHEIM PARMACEUTICALS, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004024699-A1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192748-A1 | Heterocyclic compounds | IL1B, CCL5, IL4 | POLB 2544/4885MDM2 3249/4885ERCC1 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.